(Prepared by University Professor Emeritus Bruce Holub,
Department of Human Biology
&
Nutritional Sciences, University of Guelph)
Introduction
‘Trans’ fatty acids (TFA) have become of increasing health concern to the public and health professionals alike as their levels in typical diets in North America and elsewhere have increased markedly during the past decade. Unlike naturally-occurring monounsaturated (monounsaturates) and polyunsaturated fatty acids (polyunsaturates) as found in many liquid non-hydrogenated vegetable oils, which have ‘cis’ double bonds at their unsaturation sites, TFA have ‘trans’ double bonds at the unsaturation sites within the fatty acid structure. Whereas ‘natural’ monounsaturates and polyunsaturates have curvilinear structures and are highly liquid at room temperatures, the ‘industrial’ TFA are typically linear structures that are solid fats at room temperatures due to their much higher melting points. Thus, TFA approach saturated fats in many of their physical-chemical properties.
The
‘industrial’ process known
as partial hydrogenation as performed on highly unsaturated liquid oils
(such
as soybean oil or canola oil) containing natural or ‘cis’ double bonds
free of
TFA results in the chemical transformation of these liquid oils into
solid
partially-hydrogenated oils and vegetable shortenings. These latter
commercially-processed oil products as used extensively in assorted
processed
and fast foods which impart the desired solidity, greater resilience to
oxidation and rancidity including longer shelf-lives, while allowing
for
labeling/marketing terms including ‘cholesterol-free’, ‘low in
saturated fat’,
and ‘free of animal fat’, etc. which are of receptive appeal to
consumers.
Consequently, a considerable portion of the so-called ‘monounsaturates’
in a
typical diet in
Origins, Food Sources, and Intake Levels
Origins, Food Sources, and Intake Levels
Approximately
90% of the total
TFA consumed per person daily in
Table
1 gives the estimated
intakes of the different types of fats/fatty acids and sources in a
typical
North American diet. Estimates during the past decade on the per capita
(adult)
intakes of total TFA in the North American diet have ranged from an
average
of 5 up to 10 grams/person/day.
Estimates of average TFA intakes across numerous countries
(grams/person/day)
have indicated much higher intakes in
Effects on Cardiovascular/Diabetes
Disease Risk
Effects on Cardiovascular/Diabetes Disease Risk
Epidemiological/population studies have indicated that dietary TFA, as consumed mostly in processed and fast foods, represent major dietary risk factors for coronary heart disease (CHD) in the population. A perspective study on 80,082 women from the United States followed for fourteen years indicated that the relative risk for developing CHD was almost doubled for every two percent increase in energy intake from TFA (i.e., approximately 4-5 grams daily). These findings are rather disturbing when considered in the context of the aforementioned high intakes of TFA in the North American population. Furthermore, when compared on an equal intake basis (by weight), dietary TFA was found to be a significantly greater dietary risk for CHD when compared with saturated fats (up to five- to ten-fold).
Controlled intervention trials in humans have indicated that both saturated fatty acids and TFA increase total and LDL-cholesterol levels in the circulation thereby increasing the risk of cardiovascular disease (CVD). However, TFA also lowered protective HDL-cholesterol levels whereas saturated fats did not; lowering of HDL-cholesterol levels has been associated with a substantially increased risk of CVD. In addition, TFA but not saturates tend to increase the levels of a highly atherogenic blood lipoprotein known as lipoprotein (a) which further increases the risk for CVD. The more profound increase in the ratio of circulating LDL-cholesterol: HDL-cholesterol ratio with TFA intakes as compared to equivalent amounts of saturated fats further supports population data indicating TFA to be a much great risk for CVD than saturated fats.
The impact, if any, of ‘natural’ monounsaturated TFA as found in ruminant fats (approximately 10% of the ‘industrial’ TFA intake) on the risk of CVD is still under investigation. The very small amount of unique polyunsaturated trans fat known as CLA (conjugated linoleic acid) in the diet (including ruminant fats) is also under investigation with respect to any health implications although such is unlikely based on the very low levels in our food supply.
High TFA intakes have also been implicated in other health affects such as the risk of type 2 diabetes. A major population study suggested that increased intakes of saturated fats were not significantly associated with the fourteen-year risk of type 2 diabetes risk in women whereas a two percent increase in energy consumed as TFA (approximately 4-5 grams per day) appeared to increase the risk of type 2 diabetes by 39%. There is also some evidence that high TFA intakes during pregnancy may interfere with the metabolism and deposition of important omega-3 fatty acids as are needed for the growth and development of infants during their neonatal period.
Food Labeling and Regulatory Policies
Food Labeling and Regulatory Policies
Traditional
approaches with
respect to food regulation and labeling requirements and protection
against
premature CVD have focused upon labeling for cholesterol (in ‘mg’
units) and
saturated fats (in ‘gram’ units). Consequently, labeling and marketing
terms
such a ‘cholesterol-free’ and ‘low in saturated fats’, when allowed by
regulatory agencies, have implied to many in the public sector that
such
products have been deemed to be of potential benefit with respect to
the
prevention and/or management of CVD. Unfortunately, many of these
products
contained substantial levels of ‘industrial’ TFA which might
potentially
promote rather than prevent the development of CVD via their
aforementioned
deleterious effects on risk factors such as LDL-cholesterol,
HDL-cholesterol,
and lipoprotein (a). In the present era, numerous countries have
instituted or
are implementing mandatory labeling for TFA on various food products
and/or
restrictions on the amounts allowed per food product serving. In order
to
qualify for a potential ‘trans-free’ claims on processed foods,
Canadian
labeling laws require <0.2gm of TFA per serving (plus restrictions
on the
amount of saturates present) while the corresponding cut-off is
<0.5g per
serving in the
Mandatory
labeling for TFA on
processed foods does not protect the consumer from prepared foods as
purchased
in restaurants and other outlets. Consequently, many jurisdictions (New
York city,
selected other cities in North America, selected US states, etc) are
instituting or considering legal ‘bans’ on industrial TFA in processed
and
restaurant/fast foods. The argument for such a ‘ban’ often includes
restricting
the availability of ‘industrial’ TFA at source (supply) prior to its
entry into
a wide range of processed and fast foods which would also reduce the
costs of
inspections and analytical monitoring of numerous food products.
Consumer
protection through a legislative ‘ban’ on industrially-produced TFA in
foods in
Denmark has been found to be accomplished without noticeable effects on
the availability,
price, or quality of food previously containing high amounts of
‘industrial’
TFA in that country.
Alternatives to Trans Fats
Numerous
alternatives to the use
of ‘industrial’ TFA in processed and fast foods are available. Some of
these
will require a return to some increased usage of palm and palm kernel
or other
tropical oils (containing saturated fatty acids but free of TFA from
partial hydrogenation)
alone or mixed with unsaturated vegetable oils to produce the necessary
properties for food applications. While a partial replacement of
saturated fats
for TFA may be of concern; it should be emphasized that saturated fats
are
generally considered to be a much lower dietary risk for CVD as
compared to
equivalent amounts of ‘industrial’ TFA as discussed. Other alternatives
to TFA
include high-monounsaturated vegetable oils (some via genetic
modification)
with lowered susceptibility to oxidative deterioration as compared to
highly
polyunsaturated oils and blends (or ‘inter-esterification’) of such
with more
saturated fats for appropriate textures. While butter fats typically
contain
approximately 62% of the total fat found as saturates, a 50:50 to 67:33
blend
of butter fat with highly unsaturated liquid vegetable oils (low in
saturates)
can give rise to mixtures which often have desirable physical
properties (including
spreadability, taste, etc.) and levels of saturated fats which are
below 42% of
total fat (without ‘industrial’ TFA) and which may not increase risk
factors
for CVD when consumed along with 58-66% of the total fat mixture as
natural
monounsaturates plus polyunsaturates. In some alternatives, unsaturated
vegetable oils (eg., soybean oil and canola oil) can be subjected to
complete hydrogenation
as compared to partial hydrogenation thereby giving rise to a
predominant fatty
acid product (18-carbons in chain length) known as stearic acid (fully
saturated) which, unlike other saturates, has been found not to
increase blood
cholesterol levels in controlled human trials. Thus, mixing the high
stearic acid product from complete
hydrogenation with non-hydrogenated
vegetable oils by blending or ‘inter-esterification’ techniques can
result in a
usable fat product which is TFA-free and which does not increase total
blood
cholesterol and LDL-cholesterol levels. Numerous other options are
becoming
available in the marketplace such that these technologies should help
to accelerate
the marked reduction or elimination of ‘industrial’ TFA from the food
supply if
supported by the required legislation, consumer education, and
reasonable pricing.
It is anticipated that the established health concerns with
‘industrial’ TFA
will continue to drive the impetus towards an ‘industrial TFA-free’
global
society.
|
Fat
Component |
Common
Food Source |
Avg.
Daily Consumption |
|
|
|
|
gm/day |
%
of energy (avg.) |
|
|
|
|
|
|
|
dairy products,
fatty meats palm/coconut oils |
|
|
|
Monounsaturated |
canola oil,
olive oil, |
|
|
|
‘Trans’ fatty acids |
hydrogenated
vegetable oils, shortenings, processed and |
|
|
|
Polyunsaturated
fatty |
Corn, safflower
and |
|
|
|
Polyunsaturated
fatty |
Canola oil,
soybean oil, |
|
|
|
Polyunsaturated
fatty |
|
|
|
|
|
|
|
|
|
(Data compiled by B.J. Holub) |
|||
Ascherio, A. Trans fatty acids and blood lipids. Atheroscler. Suppl. 7:25-27, 2006.
Moss, J. Labeling of trans fatty acid content in food, regulations and limits-the FDA view. Atheroscler. Suppl. 7:57-59, 2006.
Suggested Websites
U.S. Food and Drug Administration, www.fda.gov/oc/initiatives/transfat/
| |
Bruce J. Holub, Ph.D., University Professor
Emeritus
Revised October 2007 |
![]() |